Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters IgAN

The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects From Glomerular Hypercellularity and Associated Immune/Inflammatory Gene-Network- Activity in a Model of IgA Nephropathy

Learn More
Posters FSGS

Sparsentan Improves Glomerular Blood Flow and Augments Protective Tissue Remodeling in Mouse Models of Focal Segmental Glomerulosclerosis (FSGS)

Learn More
Posters

Sparsentan, the dual endothelin and angiotensin receptor antagonist (DEARA), improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes

Learn More
Posters FSGS

Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Subjects with Focal Segmental Glomerulosclerosis (FSGS)

Learn More
Posters

Physiologically Based Pharmacokinetic (PBPK) Model of Sparsentan to Evaluate Drug-Drug Interaction Potential

Learn More
Posters FSGS

Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)

Learn More
Posters

Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease

Learn More
Posters

Development of a Treatment Response Prediction Strategy for Sparsentan in Glomerular Disease

Learn More
Posters

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-label Drug-Drug Interaction Study in Healthy Adults

Learn More
Posters

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: Open-label Drug-Drug Interaction Study in Healthy Adults

Learn More
Posters FSGS

Sparsentan Improves Glomerular Blood Flow and Augments Protective Tissue Remodeling in Mouse Models of Focal Segmental Glomerulosclerosis (FSGS)

Learn More
Posters FSGS

Sparsentan for Treatment of Pediatric Patients With Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study

Learn More
Publications FSGS

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

View